» Articles » PMID: 35752779

Isolated Central Nervous System Relapses in Patients with High-risk Neuroblastoma -clinical Presentation and Prognosis: Experience of the Polish Paediatric Solid Tumours Study Group

Abstract

Although isolated central nervous system (CNS) relapses are rare, they may become a serious clinical problem in intensively treated patients with high-risk neuroblastoma (NBL). The aim of this study is the presentation and assessment of the incidence and clinical course of isolated CNS relapses. Retrospective analysis involved 848 NBL patients treated from 2001 to 2019 at 8 centres of the Polish Paediatric Solid Tumours Study Group (PPSTSG). Group characteristics at diagnosis, treatment and patterns of relapse were analysed. Observation was completed in December 2020. We analysed 286 high risk patients, including 16 infants. Isolated CNS relapse, defined as the presence of a tumour in brain parenchyma or leptomeningeal involvement, was found in 13 patients (4.5%; 8.4% of all relapses), all of whom were stage 4 at diagnosis. Isolated CNS relapses seem to be more common in young patients with stage 4 MYCN amplified NBL, and in this group they may occur early during first line therapy. The only or the first symptom may be bleeding into the CNS, especially in younger children, even without a clear relapse picture on imaging, or the relapse may be clinically asymptomatic and found during routine screening. Although the incidence of isolated CNS relapses is not statistically significantly higher in patients after immunotherapy, their occurrence should be carefully monitored, especially in intensively treated infants, with potential disruption of the brain-blood barrier.

Citing Articles

Dinutuximab Beta Maintenance Therapy in Patients with High-Risk Neuroblastoma in First-Line and Refractory/Relapsed Settings-Real-World Data.

Wieczorek A, Zebrowska U, Ussowicz M, Sokol A, Stypinska M, Dembowska-Baginska B J Clin Med. 2023; 12(16).

PMID: 37629294 PMC: 10455178. DOI: 10.3390/jcm12165252.


Central Nervous System Metastasis in Neuroblastoma: From Three Decades Clinical Experience to New Considerations in the Immunotherapy Era.

Mastronuzzi A, Colafati G, Carai A, DEgidio M, Fabozzi F, Del Bufalo F Cancers (Basel). 2022; 14(24).

PMID: 36551734 PMC: 9777007. DOI: 10.3390/cancers14246249.

References
1.
Ladenstein R, Potschger U, Valteau-Couanet D, Luksch R, Castel V, Yaniv I . Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018; 19(12):1617-1629. DOI: 10.1016/S1470-2045(18)30578-3. View

2.
Coughlan D, Gianferante M, Lynch C, Stevens J, Harlan L . Treatment and survival of childhood neuroblastoma: Evidence from a population-based study in the United States. Pediatr Hematol Oncol. 2017; 34(5):320-330. PMC: 6764456. DOI: 10.1080/08880018.2017.1373315. View

3.
Cobrinik D, Ostrovnaya I, Hassimi M, Tickoo S, Cheung I, Cheung N . Recurrent pre-existing and acquired DNA copy number alterations, including focal TERT gains, in neuroblastoma central nervous system metastases. Genes Chromosomes Cancer. 2013; 52(12):1150-66. DOI: 10.1002/gcc.22110. View

4.
Dubois S, Kalika Y, Lukens J, Brodeur G, Seeger R, Atkinson J . Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol. 1999; 21(3):181-9. DOI: 10.1097/00043426-199905000-00005. View

5.
Roderwieser A, Sand F, Walter E, Fischer J, Gecht J, Bartenhagen C . Telomerase Is a Prognostic Marker of Poor Outcome and a Therapeutic Target in Neuroblastoma. JCO Precis Oncol. 2022; 3:1-20. DOI: 10.1200/PO.19.00072. View